The global psoriasis treatment market size was USD 29.27 billion in 2023, calculated at USD 31.61 billion in 2024 and is expected to reach around USD 68.24 billion by 2034, expanding at a CAGR of 8% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Psoriasis Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Psoriasis Treatment Market, by Drug Class, 2024-2034
8.1.1. Interleukins
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. TNF Inhibitors
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Psoriasis Treatment Market, by Treatment Type, 2024-2034
9.1.1. Biologic Drugs
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Small Molecule Systemic Drugs
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Tropical Therapies
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. Psoriasis Treatment Market, by Type, 2024-2034
10.1.1. Psoriatic Arthritis
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Plaque Psoriasis
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. Psoriasis Treatment Market, by Route of Administration, 2024-2034
11.1.1. Oral
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Parenteral
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Topical
11.1.3.1. Market Revenue and Forecast (2021-2034)
12.1. Psoriasis Treatment Market, by Distribution Channel, 2024-2034
12.1.1. Hospital Pharmacies
12.1.1.1. Market Revenue and Forecast (2021-2034)
12.1.2. Online pharmacies
12.1.2.1. Market Revenue and Forecast (2021-2034)
12.1.3. Retail Pharmacies
12.1.3.1. Market Revenue and Forecast (2021-2034)
13.1. North America
13.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.1.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.1.3. Market Revenue and Forecast, by Type (2021-2034)
13.1.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.1.6.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.1.6.3. Market Revenue and Forecast, by Type (2021-2034)
13.1.6.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.1.7.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.1.7.3. Market Revenue and Forecast, by Type (2021-2034)
13.1.7.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.2.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.3. Market Revenue and Forecast, by Type (2021-2034)
13.2.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.2.6.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.6.3. Market Revenue and Forecast, by Type (2021-2034)
13.2.6.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.2.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.7. Germany
13.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.2.7.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.7.3. Market Revenue and Forecast, by Type (2021-2034)
13.2.7.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.2.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.8. France
13.2.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.2.8.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.8.3. Market Revenue and Forecast, by Type (2021-2034)
13.2.8.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.2.8.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.2.9. Rest of Europe
13.2.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.2.9.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.2.9.3. Market Revenue and Forecast, by Type (2021-2034)
13.2.9.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.2.9.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.3.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.3. Market Revenue and Forecast, by Type (2021-2034)
13.3.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.3.6.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.6.3. Market Revenue and Forecast, by Type (2021-2034)
13.3.6.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.3.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.7. China
13.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.3.7.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.7.3. Market Revenue and Forecast, by Type (2021-2034)
13.3.7.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.3.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.8. Japan
13.3.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.3.8.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.8.3. Market Revenue and Forecast, by Type (2021-2034)
13.3.8.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.3.8.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.3.9.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.3.9.3. Market Revenue and Forecast, by Type (2021-2034)
13.3.9.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.3.9.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.4.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.3. Market Revenue and Forecast, by Type (2021-2034)
13.4.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.4.6.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.6.3. Market Revenue and Forecast, by Type (2021-2034)
13.4.6.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.4.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.7. North Africa
13.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.4.7.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.7.3. Market Revenue and Forecast, by Type (2021-2034)
13.4.7.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.4.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.8. South Africa
13.4.8.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.4.8.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.8.3. Market Revenue and Forecast, by Type (2021-2034)
13.4.8.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.4.8.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.4.9. Rest of MEA
13.4.9.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.4.9.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.4.9.3. Market Revenue and Forecast, by Type (2021-2034)
13.4.9.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.4.9.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.5.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.5.3. Market Revenue and Forecast, by Type (2021-2034)
13.5.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.5.6.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.5.6.3. Market Revenue and Forecast, by Type (2021-2034)
13.5.6.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.5.6.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.5.7. Rest of LATAM
13.5.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
13.5.7.2. Market Revenue and Forecast, by Treatment Type (2021-2034)
13.5.7.3. Market Revenue and Forecast, by Type (2021-2034)
13.5.7.4. Market Revenue and Forecast, by Route of Administration (2021-2034)
13.5.7.5. Market Revenue and Forecast, by Distribution Channel (2021-2034)
14.1. Johnson & Johnson Services, Inc. (U.S.)
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Pfizer Inc. (U.S.)
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. AbbVie Inc. (U.S.)
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Novartis AG (Switzerland)
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. LEO Pharma A/S (Denmark)
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Merck & Co., Inc. (U.S.)
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. UCB S.A. (Belgium)
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Sun Pharmaceutical Industries Ltd. (India)
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Amgen Inc. (U.S.)
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Eli Lilly and Company (U.S.)
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample